Remicade is ready to fend off biosim No. 2, Johnson & Johnson executives say amid Q2 revenue miss
admin 18th July 2017 Uncategorised 0Johnson & Johnson’s Remicade is holding its own against a U.S. biosimilar rival—so much so that the company says it isn’t worried about a second entrant, which could arrive later this year. The blockbuster’s second-quarter sales did sink, but strong new meds helped fill the gap.
More: Remicade is ready to fend off biosim No. 2, Johnson & Johnson executives say amid Q2 revenue miss
Source: fierce